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IntroductIon
In Italy there are an estimated 4 million patients suffering from diabetes mellitus (DM), 
with a prevalence equal to 6.2%, which however can reach 8% if the cases of unknown dia-
betes – which, according to the Osservatorio ARNO data, correspond to 20-30% of the total 
(about 1 million Italians) – are also considered [1].
The increase in diabetes cases is closely related to three conditions: the aging of the popu-
lation, the progressive increase in obesity and the worsening of the socio-economic status [2].
The improvement in the diagnostic-therapeutic standards led to a significant reduction in 
mortality due to DM, which is however associated with an increased level of disability, that 
in turn led to the emergence of new social and health issues [3]. The management costs of 
DM, in fact, have increased over time: currently, they amount to about € 20 billion a year, of 
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AbstrAct
BACKGROUND: In Italy there are an estimated 4 million patients suffering from diabetes mellitus (DM). The most impor-
tant ocular complication of DM is diabetic retinopathy (DR), which affects about one third of diabetic patients.
AIMS: To identify, within the Lazio Region, the cohort of patients starting treatment for DME in the years 2010-2016 and 
calculating the annual cost of therapy; and to assess the appropriateness of the drugs prescribed.
METHODS: From the Health Information System of the Lazio Region were identified all subjects who, in the 2010-2016 
period, had received at least one prescription for dexamethasone intravitreal implant (i.i.) or intravitreal triamcinolone or 
ranibizumab or aflibercept or bevacizumab. For the cohort of users selected, the appropriateness of the treatment were 
evaluated calculating the number of administrations performed in the first four months of the index prescription and the 
number of administrations performed during the 12 months of treatment.
RESULTS: In 2016, 7,265 patients in the Lazio Region received at least one prescription of ranibizumab (43.0%), afliber-
cept (37.5%) and dexamethasone i.i. (19.5%). Among the 3,416 patients naïve at 6 months, who started treatment in the 
2013-2015 period and who did not switch to different drugs, 78.7% started treatment with ranibizumab, 16.0% with dexa-
methasone i.i. and 5.3% with aflibercept. The mean annual cost for the treatment of a patient with DME and naïve at 6 
months was equal to € 2,388; a total cost for only the naïve patients selected in the 2013-2015 period is therefore estimated 
at approximately € 8.2 million. The average annual cost of dexamethasone i.i. treatment was € 1,497, lower than that of 
ranibizumab (€ 2,562) and aflibercept (€ 2,485). The expenditure for patients receiving less than 3 administrations of ra-
nibizumab or aflibercept in the first 10 months of treatment was estimate equal to € 1.3 million.
CONCLUSIONS: The administrations of dexamethasone i.i. are in line with what is indicated in the prescribing informa-
tion, while for ranibizumab and aflibercept a potential under-use has been identified. A greater appropriateness of the drugs 
prescribed, accompanied by an optimal adherence to therapy, would strongly reduce the current waste of resources.
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which € 9 billion due to direct medical costs (drugs, hospitalization and care) and almost € 11 
billion absorbed by indirect and social costs, such as the loss of productivity (also on the part 
of caregivers) and the permanent disability and early retirement costs borne by the Social Se-
curity system [4]. Moreover, a recent study has shown that half of diabetic patients suffer from 
at least two other comorbidities, leading to further expenses borne by the health system [5].
Complications associated with DM mainly affect the peripheral nervous system, the car-
diovascular system, the kidneys and the visual apparatus. The most important ocular compli-
cation of DM is diabetic retinopathy (DR), recognized as the main cause of acquired blindness 
in working age adults in industrialized Countries [6-9]. Epidemiological data show that DR is 
present in about one third of diabetic patients, while severe forms – including diabetic macu-
lar edema (DME) – affect 2% of DM patients [6,10]. Progressively growing numbers in dia-
betes and its related complications suggest the need for interventions aimed on the one hand 
at preventing diabetes, and on the other at improving the management of diabetic patients and 
the treatment of complications.
On the basis of the considerations and analyses reported so far, the present work has set 
the goal of:
1. identifying, within the Lazio Region, the cohort of patients starting treatment for DME in 
the years 2010-2016 and calculating the annual cost of therapy;
2. assessing the appropriateness of the drugs prescribed according to the information re-
ported in the SmPC.
Methods
Data source
The study is based on data extracted from the Health Information System of the Lazio 
Region relating to the years 2010-2016. The pharmaceutical prescriptions have been extract-
ed from the pharmaceutical prescriptions information systems: DataWareHouse (DWH) and 
FarmED.
The DWH contains all the prescriptions forwarded by municipal and private pharmacies 
present in the regional territory for patients residing in the Lazio Region and reimbursed by 
the NHS (class A drugs), while the FarmED records the pharmaceutical services provided 
directly by the health facilities. In both databases, drugs are registered with their MA (Market-
ing Authorization) code, which allows the identification of the active ingredient (ATC code: 
Anatomical Therapeutic Chemical classification) and the dosage. For each prescription, the 
quantity dispensed, the date of shipment of the drug, the price, and the individual, anonymized 
data of the patient are reported.
Hospitalizations were selected by the Hospital Information System (SIO, Sistema Infor-
mativo Ospedaliero), which identifies and manages the analytical data of all hospital admis-
sions (in acute and post-acute cases) occurring each year in the Institutes of Hospitalization 
and Care of the Region.
The information present in the various information systems was supplemented and in-
tegrated through a deterministic record-linkage procedure, using a unique and anonymized 
patient code. The anonymized data from administrative databases are regularly used by the 
regional Health Authorities for epidemiological and administrative purposes, therefore – as 
required by the Italian legislation on the conduction of observational studies – it was not nec-
essary to request either the informed consent of the patients, nor the approval of the Ethics 
Committee of the structures involved [11].
study population
From the FarmED database, all subjects were identified who, in the 2010-2016 period, 
had received at least one prescription for one of the following drugs: dexamethasone intra-
vitreal implant (ATC: S01BA01), intravitreal triamcinolone (ATC: S01BA05), ranibizumab 
(ATC: S01LA04), aflibercept (ATC: S01LA05), bevacizumab (ATC: L01XC07).
Since the prescribing indication was not available in the information system, the patients 
being treated for DME were identified by applying the following algorithm:
 - for the users prevalent in the 2013-2015 period it was verified the presence, in the 3 years 
preceding the first prescription (index prescription), of at least one hospitalization with a 
diagnosis of DM (ICD-9-CM: 250.xx) or diabetic retinopathy (ICD9-CM: 362.x), or at 
least one prescription for hypoglycemic drugs (ATC: A10). Subjects who had at least one 
of the two conditions were defined as diabetic users of drugs for the treatment of DME;
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 - among the selected diabetic users, treatment-naïve users were identified by selecting all 
subjects with an index prescription in the 2013-2015 period, and verifying the absence of 
prescription of other study drugs in the previous six months. Patients defined as “switch-
ers” – i.e. those who, during the 12 months following the index prescription, were dis-
pensed a drug for the treatment of DME other than that of the index prescription – were 
excluded from the analysis.
For the cohort of users selected by applying the described criteria, all the dispensing of 
the study drugs occurred in the 12 months following the index prescription were evaluated, 
and the number of administrations performed – and the related annual cost – were calculated, 
based on the regional price of the drug as indicated in the FarmED.
In addition, in order to assess the appropriateness of the treatment, the number of ad-
ministrations performed in the first four months of the index prescription and the number of 
administrations performed during the 12 months of treatment were calculated.
The four-month window allows to evaluate the effective administration of the loading 
dose within a reasonable time, since the treatment with ranibizumab should be initiated with 
three or more consecutive monthly injections, while that with aflibercept should be started 
with one injection per month for three consecutive doses. The expected percentage of patients 
with three injections in the first four months, for both drugs, is therefore close to 100%.
results
Patients in the Lazio Region, who in 2016 had received at least one prescription for the 
study drugs, amounted to 7,265, 43.0% of whom received ranibizumab, 37.5% aflibercept and 
the remaining 19.5% dexamethasone intravitreal implant (i.i.). Prescriptions for intravitreal 
triamcinolone and bevacizumab were not identified within the information systems analyzed. 
As reported in Table I, the number of subjects treated has been steadily increasing from 2010 
to 2016. In 2016, around 600 subjects – 8.8% of the total – received prescriptions for two 
or more drugs other than those being studied: such patients, in subsequent analyses, will be 
referred to as “switchers”.
Among total users, the mean proportion of patients with a diagnosis of diabetes confirmed 
by previous hospitalizations or prescriptions of hypoglycemic drugs is equal to 35.0%, and in 
2016 it varies between the 52.1% of subjects treated with dexamethasone i.i. and the 26.2% 
of aflibercept users (Table II).
The number of subjects naïve at 6 months was approximately 1,500 per year; in 2016 the 
percentage of naïve subjects out of the total number of users was 64.1% for dexamethasone 
i.i., 56.6% for ranibizumab and 49.8% for aflibercept (Table III).
aTC Drug
Patients (no.)
2010 2011 2012 2013 2014 2015 2016
S01BA01 Dexamethasone i.i. - 104 405 601 939 1,267 1.544
S01LA04 Ranibizumab 303 1,020 1,763 4,421 4,753 4,074 3.396
S01LA05 Aflibercept - - - 91 980 1,946 2.962
Total 303 1,124 2,159 4,941 6,122 6,634 7,265
Switchers (≥ 2 drugs) - - 9 172 550 653 637
Table i. Subjects who received at least one study drug, treated for DME or other conditions (Lazio 2010-2016)
aTC Drug
2013 2014 2015 2016
no. % no. % no. % no. %
S01BA01 Dexamethasone i.i. 234 38.9 406 43.2 670 52.9 805 52.1
S01LA04 Ranibizumab 1,641 37.1 1,782 37.5 1,488 36.5 1,175 34.6
S01LA05 Aflibercept 33 36.3 251 25.6 435 22.4 777 26.2
Total 1,812 36.7 2,218 36.2 2,304 34.7 2,450 33.7
Switchers (≥ 2 drugs) 96 55.8 221 40.2 289 44.3 307 48.2
Table ii. Diabetic subjects who received at least one study drug. Absolute values and % of patients with DME out of total users (Lazio 
2013-2016)
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i.i. and the 76.2 treated of those treated with aflibercept (Table IV). The distribution by year 
of the subjects treated shows a reduction in the use of ranibizumab and an increase in that of 
dexamethasone i.i. (+54.9%) and aflibercept (Figure 1).
The mean number of dispensing occurred within one year of the first prescription is equal 
to 1.6 for patients treated with dexamethasone i.i., 3.3 for ranibizumab and 3.6 for aflibercept. 
The starting year of treatment does not seem to affect the average number of administrations 
per subject; in fact, variability is minimal for dexamethasone i.i. and ranibizumab, while for 
aflibercept there is an increase from 3.3 to 4 yearly administrations (Figure 2).
The administrations of dexamethasone i.i. are in line with what is indicated in the prescrib-
ing information, while for ranibizumab and aflibercept – although a precise number of admin-
istrations is not specified – a potential under-use has been identified. This data is confirmed by 
the distribution of the subjects by number of administrations received within 4 and 12 months 
from the first administration. In the first 4 months, 88.5% of patients treated with dexametha-
sone i.i. received a dose, 10.6% received two and the remaining 0.9% received three. With 
regard to ranibizumab and aflibercept, on the other hand, only 36.8% and 39.0% of patients 
received – during the first three months – a number of prescriptions consistent with what 
indicated in the prescribing information, while 55% of patients received a maximum of two 
aTC Drug Men (no.)
Mean age 
(years)
Women 
(no.)
Mean age 
(years)
Total (no.)
Mean age 
(years)
S01BA01 Dexamethasone i.i. 317 67.6 229 70.1 546 68.7
S01LA04 Ranibizumab 1,483 69.3 1,205 72.0 2,688 70.5
S01LA05 Aflibercept 101 74.6 81 78.3 182 76.2
Total 1,901 69.3 1,515 72.1 3,416 70.5
Table iV. Cohort of diabetic subjects naïve at 6 months who did not switch to different drugs than the initial one. Distribution by gender 
and age (Lazio 2013-2015)
Figure 1. Cohort of diabetic subjects naïve at 6 months. Distribution by drug 
(Lazio 2013-2015)
Figure 2. Cohort of diabetic subjects naïve at 6 months. Mean yearly dispensing (Lazio 2013-2015)
Figure 3. Distribution of naïve diabetic subjects by number of dispensing in the first 4 months after the first administration (Lazio 2013-2015)
Figure 4. Distribution of naïve diabetic subjects by number of dispensing in the first 12 months after the first administration (Lazio 2013-2015)
In order to highlight the average number 
of annual dispensing and the related cost, it 
was selected the cohort of patients naïve at 6 
months, who started treatment in the 2013-
2015 period and who did not switch to dif-
ferent drugs than the initial one. 
In this way, 3,416 newly treated sub-
jects were identified, of whom 78.7% started 
treatment with ranibizumab, 16.0% with 
dexamethasone i.i. and the remaining 5.3% 
with aflibercept. The gender distribution of 
users does not vary significantly between the 
different drugs analyzed (about 55% males 
for ranibizumab and aflibercept and 58% for 
dexamethasone i.i.), while the mean age is 
70.5 years, varying between the 68,7 years 
of the subjects treated with dexamethasone 
aTC Drug
2013 2014 2015 2016
no. % no. % no. % no. %
S01BA01 Dexamethasone i.i. 167 71.4 266 65.5 416 62.1 516 64.1
S01LA04 Ranibizumab 1,402 85.4 1,152 64.6 922 62.0 665 56.6
S01LA05 Aflibercept 10 30.3 103 41.0 204 46.9 387 49.8
Switchers (≥ 2 drugs) 15 15.6 11 5.0 15 5.2 21 6.8
Table iii. Diabetic subjects naïve at 6 months. Absolute values and % of total diabetic users (Lazio 2013-2016)
111Farmeconomia. Health economics and therapeutic pathways 2019; 20(1)
F. S. Mennini,  L. Lombardozzi, A. Mecozzi, P. Sciattella
i.i. and the 76.2 treated of those treated with aflibercept (Table IV). The distribution by year 
of the subjects treated shows a reduction in the use of ranibizumab and an increase in that of 
dexamethasone i.i. (+54.9%) and aflibercept (Figure 1).
The mean number of dispensing occurred within one year of the first prescription is equal 
to 1.6 for patients treated with dexamethasone i.i., 3.3 for ranibizumab and 3.6 for aflibercept. 
The starting year of treatment does not seem to affect the average number of administrations 
per subject; in fact, variability is minimal for dexamethasone i.i. and ranibizumab, while for 
aflibercept there is an increase from 3.3 to 4 yearly administrations (Figure 2).
The administrations of dexamethasone i.i. are in line with what is indicated in the prescrib-
ing information, while for ranibizumab and aflibercept – although a precise number of admin-
istrations is not specified – a potential under-use has been identified. This data is confirmed by 
the distribution of the subjects by number of administrations received within 4 and 12 months 
from the first administration. In the first 4 months, 88.5% of patients treated with dexametha-
sone i.i. received a dose, 10.6% received two and the remaining 0.9% received three. With 
regard to ranibizumab and aflibercept, on the other hand, only 36.8% and 39.0% of patients 
received – during the first three months – a number of prescriptions consistent with what 
indicated in the prescribing information, while 55% of patients received a maximum of two 
aTC Drug Men (no.)
Mean age 
(years)
Women 
(no.)
Mean age 
(years)
Total (no.)
Mean age 
(years)
S01BA01 Dexamethasone i.i. 317 67.6 229 70.1 546 68.7
S01LA04 Ranibizumab 1,483 69.3 1,205 72.0 2,688 70.5
S01LA05 Aflibercept 101 74.6 81 78.3 182 76.2
Total 1,901 69.3 1,515 72.1 3,416 70.5
Table iV. Cohort of diabetic subjects naïve at 6 months who did not switch to different drugs than the initial one. Distribution by gender 
and age (Lazio 2013-2015)
Figure 1. Cohort of diabetic subjects naïve at 6 months. Distribution by drug 
(Lazio 2013-2015)
Figure 2. Cohort of diabetic subjects naïve at 6 months. Mean yearly dispensing (Lazio 2013-2015)
Figure 3. Distribution of naïve diabetic subjects by number of dispensing in the first 4 months after the first administration (Lazio 2013-2015)
Figure 4. Distribution of naïve diabetic subjects by number of dispensing in the first 12 months after the first administration (Lazio 2013-2015)
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doses, and approximately 1 in 4 patients received a single injection during the first 4 months 
of treatment (Figure 3). Analyzing the number of administrations in the first 10 months, it 
is noted that 89.9% of patients treated with dexamethasone i.i. received 2 administrations, 
while patients receiving at most 2 administrations of ranibizumab and aflibercept are 38.5% 
and 33.5%, respectively, indicating a strong underuse and, consequently, a high proportion of 
inappropriateness (Figure 4).
The analysis repeated by stratifying by year of first treatment confirms the previous re-
sults, with a stability of the data with regard to dexamethasone i.i. and ranibizumab, while for 
aflibercept the proportion of undertreated patients would seem to decrease, with the propor-
tion of subjects with at most 3 administrations in the first 10 months of treatment decreasing 
from 70.6% to 58.8% (Table VI).
The mean annual cost for the treatment of a patient with DME and naïve at 6 months was 
equal to € 2,388; a total cost for only the naïve patients selected in the 2013-2015 period is 
therefore estimated at approximately € 8.2 million. The average annual cost of dexametha-
sone i.i. treatment was € 1,497, lower than that of ranibizumab (€ 2,562) and aflibercept (€ 
2,485). No significant differences with reference to the year of start of the first treatment have 
been identified (Table VII).
Finally, to get an idea of the expenditure for inappropriately treated or undertreated pa-
tients, the cost of the drugs dispensed to patients receiving less than 3 administrations of 
ranibizumab or aflibercept in the first 10 months of treatment was considered. The total esti-
mate was equal to € 1.3 million, which probably represents, for the regional Health System, a 
significant cost that does not provide any benefits to patients.
dIscussIon
Diabetic macular edema is the most serious ocular complication of DM, and one of the 
main causes of vision loss and blindness in industrialized Countries [12]. The progressive 
aging of the population – and the expected increase in the global prevalence of diabetes 
– will lead in the coming years to a marked increase in the ocular complication-related 
burden, including DME. Early diagnosis and effective treatment are essential factors in pre-
venting visual impairment and avoiding the economic consequences and the social impact 
of vision loss.
Drug Year
Patients 
(no.)
Dispensing (no.)
1 2 3 4 5 6 7 8 9 10 >10
Dexamethasone i.i. 2013 142 70.4 23.2 5.6  - 0.7 - - - - - -
2014 184 64.7 25.0 9.2 1.1 - - - - - - -
2015 220 62.7 24.5 8.6 3.6 0.5 - - - - - -
Ranibizumab 2013 1,317 22.4 16.3 29.0 13.2 8.0 6.4 2.7 0.8 0.8 0.3 0.2
2014 823 20.8 18.1 31.7 11.9 8.6 6.2 1.3 0.9 0.2  - 0.2
2015 548 20.4 17.2 30.3 12.8 7.7 7.5 2.9 1.1 0.2 - -
Aflibercept 2013 7 28.6 14.3 28.6  - 28.6 - - - - - -
2014 61 23.0 19.7 27.9 9.8 13.1 6.6  -  - - - -
2015 114 13.2 14.9 30.7 13.2 13.2 8.8 2.6 0.9  - - 2.6
Table Vi. Distribution of naïve diabetic subjects by year and number of dispensing in the first 10 months after the first administration 
(Lazio 2013-2015)
aTC Drug
average cost (€/year)
2013 2014 2015 2013-2015
S01BA01 Dexamethasone i.i. 1,326 1,514 1,593 1.497
S01LA04 Ranibizumab 2,911 2,296 2,124 2.562
S01LA05 Aflibercept 2,407 2,273 2,604 2.485
Total 2.755 2,160 2,054 2,388
Table Vii. Cohort of diabetic subjects naïve at 6 months. Average annual cost of treatment (Lazio 2013-2015)
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Our analysis, based on real-world data, allowed to estimate the number of patients in the 
Lazio region treated for DME in the years 2013-2016, confirming the growth trend expected 
on the basis of the epidemiological data. Diabetic subjects with at least one drug dispensed 
for the treatment of DME have in fact increased from about 1,800 in 2013 to 2,450 in 2016.
Based on literature data – which in 2015 estimated the diabetic population of Lazio at 
6.6% of residents [13] and an incidence of DME with visual impairment among diabetics of 
2.0% [14] – the population of DME patients in 2015 was approximately 7,800. In our analy-
sis, DME patients who received at least one treatment in 2015 were 2,300, which means that 
health information systems have identified about 29.7% of total patients. Even considering the 
recording and tracking errors typical of the information systems, the remaining portion could 
be made up of subjects who do not receive any drug therapy.
Currently, the drug therapy for the treatment of DME includes the use of corticosteroids 
or anti-VEGFs (vascular endothelial growth factor receptor antagonists) [15]. Corticosteroids 
can be administered locally (intravitreal injections) or by controlled-release intravitreal im-
plants, which have a therapeutic effectiveness sustained over time and a frequency of 2-3 
administrations per year, while anti-VEGFs are administered by intravitreal injection approxi-
mately every 4-6 weeks [15].
The results of our analysis allowed to estimate the average number of annual adminis-
trations in the cohort of patients/users in the 2013-2015 period, highlighting – among the 
subjects treated with dexamethasone i.i. – a substantial adherence to the prescribing indica-
tion, and at the same time a substantial proportion of patients treated with ranibizumab and 
aflibercept in a potentially inappropriate way (lower number of administrations than in com-
mon clinical practice).
The issue of adherence to treatment in DME was addressed in a position paper of the 
Italian Pharmacology Society (SIF, Società Italiana di Farmacologia) [16], which highlights 
how in real-life observational studies the number of anti-VEGF administrations is always 
lower than the expected administration schedule while, in the case of corticosteroid intravit-
real implant, a number of administrations variable from 1 to 3 was found, in line with what 
specified in the prescribing information. 
As reported in the literature [17-21], in the treatment of DME the lack of adherence to the 
recommended therapeutic regimen results in a missed or reduced improvement in visual acu-
ity. In addition, it represents one of the main problems of the National Health Service, since it 
causes the use of resources without a corresponding clinical benefit. The delay or lack of treat-
ment can in fact lead to the loss of vision, with subsequent implications for the patient such 
as a reduced quality of life and autonomy, social isolation and reduction of job opportunities. 
All this, in the long term, translates into an increase in the costs borne by the Health Service 
and society [22].
In our analysis, the potential inappropriateness identified in the treatment with ranibizum-
ab and aflibercept leads to an expense, in relation to patients treated with less than 3 yearly 
administrations (instead of the expected 6-7), of € 1.3 million, which is likely unaccompanied 
by any clinical benefit. In a period of reduction of the available resources – and therefore of 
spending review – it is necessary to evaluate the allocation of resources and the adherence of 
patients to the prescribed treatments, in order to ensure the access to treatment to the greatest 
possible number of patients.
conclusIons
Designing a care pathway that tends to guarantee a greater appropriateness of the drugs 
prescribed, accompanied by an optimal adherence to therapy, would strongly reduce, in the 
specific case of the treatment of DME, the current waste of resources (in fact, if the interven-
tions are inappropriate and characterized by poor adherence, they represent a waste), with a 
consequent increase in the effectiveness of interventions and a correct use of resources.
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